Skip to content

Multiomics Drug Approvals KP

Gwênlyn Glusman edited this page Sep 4, 2024 · 5 revisions

Description: The Multiomics Drug Approvals KP, created and maintained by the Multiomics Provider, provides assertions about regulatory approvals of drug interventions for treating diseases, and observations of off-label use of drug interventions. These assertions and observations are derived through integration of content from DailyMed and the FDA's adverse-event reporting system (FAERS).

Example: The Multiomics Drug Approvals KP shows that leuprolide treats prostate cancer. This assertion is supported by 11 approved New Drug Applications, including NDA019732, and 7 product labels, including LEUPROLIDE ACETATE DEPOT- leuprolide acetate kit. The Multiomics Drug Approvals KP also shows that risperidone is applied to treat ADHD, off-label. This observation is supported by tens of thousands of case reports in FAERS.

The graph currently uses biolink:treats and biolink:applied_to_treat as predicates. Node categories include biolink:SmallMolecule, biolink:ChemicalEntity, and biolink:MolecularMixture for the interventions, and biolink:Disease and biolink:PhenotypicFeature for the conditions.

Modes of access:

Data Sources Used -

  • FDA DailyMed
  • FDA FAERS
Clone this wiki locally